Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BFRI Biofrontera
0.918-0.007-0.76%
Close
01/27 16:00 ET
0.9180.0000.00%
Post Mkt Price 01/27 17:10 ET
High
0.930
Open
0.910
Turnover
58.15K
Low
0.850
Pre Close
0.925
Volume
64.56K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Biofrontera Inc. (NASDAQ:BFRI) Short Interest Up 17.3% in December
Biofrontera Inc. (NASDAQ:BFRI – Get Rating) was the recipient of a significant growth in short interest in the month of December. As of December 30th, there was short interest totalling 467,400 share
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersBellerophon Therapeutics (NASDAQ:BLPH) shares increased by 18.4% to $2.9 during Wednesday's after-market session. This security traded at a volume of 416.2K shares come close, making up 40.3% o
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersShuttle Pharmaceuticals (NASDAQ:SHPH) stock rose 17.5% to $2.08 during Thursday's after-market session. At the close, Shuttle Pharmaceuticals's trading volume reached 565.4K shares. This is 40.
Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
05:30 PM EST, 01/09/2023 (MT Newswires) -- Biofrontera Inc. (BFRI), a dermatological products group, said it dosed its first patient in a phase-3 multicenter study evaluating the treatment of actinic
Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that the first
Biofrontera Inc. Sees Prelim. Q4 Revenue $102.M-$10.4M
Revenues for the fourth quarter of 2022 are anticipated to be in the range of approximately $10.2 million to $10.4 million, an increase of approximately 12% compared with the fourth quarter of 2021. T
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022
WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, u
Biofrontera (NASDAQ:BFRI) Trading Down 1.1%
Biofrontera Inc. (NASDAQ:BFRI – Get Rating) fell 1.1% on Monday . The stock traded as low as $0.91 and last traded at $0.93. 3,094 shares were traded during mid-day trading, a decline of 100% from t
Biofrontera's Return On Capital Employed Overview
Benzinga Pro data, Biofrontera (NASDAQ:BFRI) reported Q3 sales of $4.32 million. Earnings fell to a loss of $2.57 million, resulting in a 201.88% decrease from last quarter. In Q2, Biofrontera brought
Biofrontera Has Received A Notice Of Allowance For Its U.S. Patent Application 17/269,816 Titled "Photodynamic Therapy Comprising Two Light Exposures At Different Wavelengths (For The Prevention Or Treatment Of Dermatological Disease)"
Biofrontera Has Received A Notice Of Allowance For Its U.S. Patent Application 17/269,816 Titled "Photodynamic Therapy Comprising Two Light Exposures At Different Wavelengths (For The Prevention Or Tr
Company Overview
More
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.
CEO： Ms. Erica Monaco, C.P.A.
Market： NASDAQ
Listing Date： 10/29/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet